Back to discover
Drug

Retinol palmitate

In clinical development
Emerging researchEarly-to-mid development
Also known as Aquasol A, Infuvite, Infuvite Pediatric, Lazer Creme+7 more

Aquasol A, Infuvite, Infuvite Pediatric, Lazer Creme, Retinol, VITAMIN A PALMITATE, Vital E- A + D3, Vital E- Repro, Vitamin A, Vitamin A (Palmitate), RETINYL PALMITATE.

RxNorm35406ChEMBLCHEMBL1675UNII1D1K0N0VVC
2
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

An Investigation of Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation

Clinical trial2025-04-16Results posted · ClinicalTrials.gov

An Investigation of Vitamin A Palmitate Supplementation in Patients With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation

Clinical trial2025-04-15Results posted · ClinicalTrials.gov

LOW-DOSE SUPPLEMENTATION WITH RETINOL IMPROVES RETINAL FUNCTION IN EYES WITH AGE-RELATED MACULAR DEGENERATION BUT WITHOUT RETICULAR PSEUDODRUSEN.

Research2023-09-01Retina (Philadelphia, Pa.)

Formulation of Retinyl Palmitate-loaded Topical Ethosomes for Treatment of Acne Vulgaris: a Split-face Comparative Clinical Study

Clinical trial2020-11-30Completed · ClinicalTrials.gov

Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial.

Research1996-11-01Journal of the National Cancer Institute

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Retinol palmitate
Aliases & brands
Aquasol AInfuviteInfuvite PediatricLazer CremeRetinolVITAMIN A PALMITATEVital E- A + D3Vital E- ReproVitamin AVitamin A (Palmitate)RETINYL PALMITATE
RxNorm CUI
35406
ChEMBL ID
CHEMBL1675
UNII
1D1K0N0VVC

Clinical trials

3 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
3
registered trials across all phases
LATEST COMPLETION 2023
3
Completed
PHASE DISTRIBUTIONn = 3
Early Phase 12Phase 21

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
19962023
Major research themes2
Macular Degeneration1Retinal Drusen1
Journals, researchers & institutions
Top journals
  • Journal of the National Cancer Institute1
  • Retina (Philadelphia, Pa.)1
Leading researchers
  • Balmes J1
  • Barnhart S1
  • Brodkin CA1
  • Cherniack MG1
  • Cukras CA1
  • Cullen MR1
  • Glass A1
  • Goodman GE1
Leading institutions
free-text, unnormalised
  • Division of Epidemiology and Clinical Applications1
  • Fred Hutchinson Cancer Research Center1
  • National Eye Institute1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

beta Carotene

Studied across the same disease area as Retinol palmitate in the shared literature.

1 shared disease1 shared paper
Vitamin A

Studied across the same disease area as Retinol palmitate in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials